Stock Market logoStock Market Station

All the stock market news, every minute updated!

03 August 2021
13:29 hour

Adamis gets FDA greenlight for tempol human studies in COVID-19

Seeking Alpha

22/02/2021 - 17:14


READ THE FULL ARTICLE ON SEEKING ALPHA

Related headlines:

  1. Adamis Pharma climbs as NIH highlights TEMPOL as potential COVID-19 therapy (03/06/2021 - Seeking Alpha)

    [visit article]
  2. Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19 (07/06/2021 - Seeking Alpha)

    [visit article]
  3. Eledon Pharmaceuticals gets Health Canada greenlight for AT-1501 human trials (26/07/2021 - Seeking Alpha)

    [visit article]
  4. ORIC Pharmaceuticals gets FDA greenlight for ORIC-533 human trials (28/06/2021 - Seeking Alpha)

    [visit article]
  5. Adamis begins clinical trial start-up activities for COVID drug; shares rise 5% (11/06/2021 - Seeking Alpha)

    [visit article]
  6. The impact of COVID-19 on professional courses and their future in the post COVID era (22/03/2021 - Financial Express)
    Crisis gives birth to new opportunities. COVID-19 is one of the biggest crisis the human race saw in the recent past. It created a huge impact on every sphere of human life.
    [visit article]
  7. Covid-19: Can dogs sniff coronavirus? Here’s what studies suggest (26/05/2021 - Financial Express)
    Now that some very positive data from two studies has surfaced, does this mean that the testing for coronavirus will now be done by sniffer dogs
    [visit article]
  8. : Einhorn’s Greenlight has classic response to 2021 first quarter loss as the stock market is at records: ‘The wind is now at our backs’ (15/04/2021 - Market Watch)
    David Einhorn’s Greenlight Capital delivered a lackluster quarter in the first three months of 2021 but the hedge-fund luminary vowed to earn his fees in coming months, suggesting that shifting appetite for value stocks will ultimately give way to better performance.
    [visit article]
  9. Adamis Pharmaceuticals misses on revenue (15/04/2021 - Seeking Alpha)

    [visit article]
  10. Adamis resubmits ZIMHI opioid overdose treatment NDA (17/05/2021 - Seeking Alpha)

    [visit article]
  11. Adamis Pharma soars 18% after FDA accepts Zimhi application for review (09/06/2021 - Seeking Alpha)

    [visit article]
  12. Adamis strengthens patent portfolio for ZIMHI opioid overdose treatment (17/02/2021 - Seeking Alpha)

    [visit article]
  13. The Conversation: COVID-19 — but not the vaccine — may reduce male fertility (26/07/2021 - Market Watch)
    These small studies find reduced sperm counts and a risk for erectile dysfunction from COVID-19.
    [visit article]
  14. Covid-19 vaccine: Dr Reddy’s seeks emergency use approval for Sputnik V; Why it is important for India (20/02/2021 - Financial Express)
    Dr Reddy’s Laboratories has been conducting human trials of the Sputnik-V vaccine in the country with more than 1500 participants. While phase 2 of the human trial has already been wrapped up by the Indian company, the third phase is expected to come to a close by February 21.
    [visit article]
  15. Greenlight Capital reports Q4 results (10/03/2021 - Seeking Alpha)

    [visit article]
  16. U.S. is conducting studies to determine if COVID booster shots are needed (20/07/2021 - Seeking Alpha)

    [visit article]
  17. Nkarta gets greenlight from the FDA for NKX019 cancer study (28/04/2021 - Seeking Alpha)

    [visit article]
  18. Organicell's osteoarthritis treatment zofin IND gets FDA greenlight (21/04/2021 - Seeking Alpha)

    [visit article]
  19. New studies shed light on lasting COVID-19 immunity in vaccinated individuals (26/05/2021 - Seeking Alpha)

    [visit article]
  20. ImmunityBio gets South Africa regulatory nod for T-Cell COVID-19 vaccine studies (14/07/2021 - Seeking Alpha)

    [visit article]
  21. iBio says successful in preclinical studies for subunit COVID-19 vaccine candidate (16/07/2021 - Seeking Alpha)

    [visit article]
  22. FDA gives NLS Pharmaceutics greenlight for mid-stage Quilience narcolepsy trial (15/07/2021 - Seeking Alpha)

    [visit article]
  23. Pfizer begins late-stage studies to test COVID-19 vaccine in kids (08/06/2021 - Seeking Alpha)

    [visit article]
  24. Graphic Packaging gains after Greenlight discloses owning in Q2 letter (26/07/2021 - Seeking Alpha)

    [visit article]
  25. Greenlight's Einhorn says 'quasi-anarchy' rules the market: At the Open (16/04/2021 - Seeking Alpha)

    [visit article]
  26. David Einhorn's Greenlight Capital adds SPACs, exits NCR (17/05/2021 - Seeking Alpha)

    [visit article]
  27. Ultragenyx gets FDA greenlight for UX053 Glycogen Storage Disease trials (08/03/2021 - Seeking Alpha)

    [visit article]
  28. NanoViricides shares rally 29% on effectiveness of COVID-19 drug candidates in cell culture studies (02/03/2021 - Seeking Alpha)

    [visit article]
  29. Greenlight Capital Re invests in tech-driven amateur sports insurer (21/04/2021 - Seeking Alpha)

    [visit article]
  30. Greenlight's Einhorn takes on lax regulators, GameStop short squeeze in Q1 letter (15/04/2021 - Seeking Alpha)

    [visit article]
  31. Sorrento gets FDA greenlight for early-stage CD38 DAR-T multiple myeloma study (02/08/2021 - Seeking Alpha)

    [visit article]
  32. Greenlight Capital Re Q4 investment income bolstered by Solasglas fund gains (10/03/2021 - Seeking Alpha)

    [visit article]
  33. Pluristem brings Phase II COVID-19 ARDS studies to clinical readout; topline data expected in Q4 (08/07/2021 - Seeking Alpha)

    [visit article]
  34. Oxford initiating human challenge COVID-19 study (19/04/2021 - Seeking Alpha)

    [visit article]
  35. ORYZON gets Spanish Drug Agency greenlight for mid-stage vafidemstat schizophrenia trial (13/07/2021 - Seeking Alpha)

    [visit article]
  36. Stoke Therapeutics gets MHRA greenlight for early-stage Dravet syndrome study (30/03/2021 - Seeking Alpha)

    [visit article]
  37. I-Mab gets China NMPA greenlight for early-stage felzartamab chronic disease trial (25/06/2021 - Seeking Alpha)

    [visit article]
  38. Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression (14/06/2021 - Seeking Alpha)

    [visit article]
  39. Prices will move much higher because of structural shortages - David Einhorn's Greenlight Capital (26/07/2021 - Seeking Alpha)

    [visit article]
  40. : Young, healthy adults will be deliberately reinfected with COVID-19 to boost vaccine development (19/04/2021 - Market Watch)
    Researchers at the University of Oxford have launched a "human challenge" trial to investigate what happens when someone who has recovered from COVID-19 is re-exposed to the virus
    [visit article]
  41. COVID-19 vaccine: Should the gap between monitoring two doses be increased? (02/03/2021 - Financial Express)
    The vaccination programme in India is currently monitoring the two doses of Coronavirus vaccines between a prescribed gap of 28 days. The findings based on the phase 3 regulatory studies have indicated that the gap interval between the first and second dose of COVID-19 vaccine should at least be four to six weeks.
    [visit article]
  42. Mexico Exports - Prepared Human & Animal Blood, Antisera, Others (13/02/2021 - Trading Economics)
    Exports - Prepared Human & Animal Blood, Antisera, Others in Mexico increased to 23350 USD THO in December from 16786 USD THO in November of 2020. Exports - Prepared Human & Animal Blood, Antisera, in Mexico averaged 6327.07 USD THO from 1993 until 2020, reaching an all time high of 35821 USD THO in September of 2009 and a record low of 346 USD THO in August of 1994. This page includes a chart with historical data for Mexico Exports of Prepared Human & Animal Blood, Antiser.
    [visit article]
  43. Jubilant Pharmova’s arm completes studies using novel oral formulation of Remdesivir (20/04/2021 - Money Works 4 Me)
    Jubilant has sought authorization for additional studies for this novel oral formulation from the Drug Controller General of India
    [visit article]
  44. Online studies during lockdown and impact on children’s eye sight (23/06/2021 - Financial Express)
    Children are continuously using mobile phones, laptops and computers for online studies, playing games, watching web series and staring at screens more in this lockdown.
    [visit article]
  45. Happiest Minds’ case studies recognized with 2021 ISG Digital Case Study Awards (26/07/2021 - Money Works 4 Me)
    ISG selected case studies from 39 providers for this year’s Awards from a record of nearly 250 submissions
    [visit article]
  46. Sony launches Bravia X90J 55-inch Ultra-HD HDR TV in India, claims it can think like a human brain (10/06/2021 - Financial Express)
    The main USP of this smart TV is its Cognitive Processor XR which, in the words of Sony, allows it to think like a human brain
    [visit article]
  47. Coronavirus in India Live News: PM Modi to meet experts today to review oxygen & medicine availability; India reports 3.92 lakh Covid cases (02/05/2021 - Financial Express)
    Coronavirus Daily Cases and Deaths in India, Covid-19 India Lockdown, May 1 Phase 3 vaccine drive, Day 2 vaccination drive for 18+ years, CoWIN Covid-19 Vaccination Registration, May 2: Prime Minister Narendra Modi is expected to review the human resource situation, in relation to the Covid-19 pandemic, and ways to augment it.
    [visit article]
  48. Freedom House Report: Centre fires point-wise rebuttal after global watchdog downgrades India to ‘partly free’ (06/03/2021 - Financial Express)
    Refuting the allegation of human rights violations, the ministry said that the Indian Constitution provides for adequate safeguards under various statutes, including the protection of human rights.
    [visit article]
  49. Mexico Imports - Dolls Representing Only Human Beings, & Parts (12/06/2021 - Trading Economics)
    Imports - Dolls Representing Only Human Beings, & Parts in Mexico remained unchanged at 0 USD THO in April from 0 USD THO in March of 2021. This page includes a chart with historical data for Mexico Imports of Dolls Representing Only Human Beings,.
    [visit article]

For more information mailto [email protected]. Disclaimer.